A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

Summary

This is a Phase 2, randomized, placebo-controlled, and observer-blind study in healthy adults. The study will evaluate the safety, tolerability, and immunogenicity of the SARS-CoV-2 RNA vaccine candidate against COVID-19: As 2 doses (at two different dose levels), separated by 28 days or as 1 dose In adults 18 years of age and older

Timeline

Start

2021-01-07

Primary completion

2022-03-01

Completion

2022-03-01

Outcome

Outcome not reported

Stopped (Business): “A decision was made to terminate the study for operational/business reasons. The study was not terminated for reasons of safety or immunogenicity.”

Drugs

Indications